The Q3 2026 DECLARATION readout is the primary catalyst. Monitor for any pre-read or event-rate updates before then. The cash runway ($184M + $20M ATM) should fund through data and potential launch, but the widening loss and trial delay add execution risk. The ATM usage signals ongoing dilution needs.
IVVD drugs
IVVD drug pipeline →Price Chart
Executive Summary
Invivyd reported Q1 2026 PEMGARDA net product revenue of $13.7M (+22% YoY), but net loss widened to $41.4M from $16.3M a year ago due to a surge in R&D spending on the DECLARATION pivotal trial. The DECLARATION trial was upsized by ~500 subjects, pushing top-line data to Q3 2026, and the company raised ~$20M via ATM in April. Revenue growth is positive but the accelerating cash burn and trial delay are material concerns for a pre-profit biotech.
Key Financial Metrics
Key Facts
- Q1 2026 PEMGARDA net product revenue $13.7M, up 22% YoY from $11.3M
- Net loss widened to $41.4M from $16.3M YoY, driven by R&D spend of $30.7M (up from $10.6M)
- DECLARATION Phase 3 trial upsized by ~500 subjects; top-line data now expected Q3 2026 (vs prior mid-2026)
- Cash and cash equivalents $184.2M at March 31, 2026; raised ~$20M in April 2026 via ATM
- IDMC recommended reduction of post-dose monitoring from 2 hours to 30 minutes based on safety data
- In vitro data confirmed neutralizing activity of pemivibart and VYD2311 against BA.3.2.2 (Cicada) variant
- Agreed with FDA on initial pediatric study plan (DRUMMER) for VYD2311 BLA support
Financial Impact
Revenue growth of 22% YoY to $13.7M, but operating loss more than doubled to $43.1M from $16.9M
Risk Factors
- DECLARATION trial delay to Q3 2026 increases uncertainty and cash burn
- Net loss more than doubled YoY to $41.4M, with R&D spend tripling
- Additional ~$20M ATM dilution in April 2026; further capital raises likely
- PEMGARDA EUA dependent on variant susceptibility; revenue concentration risk
- Pre-revenue on VYD2311; binary catalyst risk on Phase 3 data
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-222762 |
| Document: d120795dex992.htm | 0001193125-26-222762 |
| Document: d120795d8k.htm | 0001193125-26-222762 |
| Document: 0001193125-26-222762-index-headers.html | 0001193125-26-222762 |
| Document: 0001193125-26-222762-index.html | 0001193125-26-222762 |
| Document: 0001193125-26-222762.txt | 0001193125-26-222762 |
| 8-K Data (Synthetic) | 0001193125-26-222762 |
Track record
19 reports on IVVD
3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +35.85% at T+20 after the Jul 6, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 6/10 Entry $0.5603 Now $0.5380 −3.98% settles Nov 23
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $0.5815 to $0.5744 Now $0.5380 −7.48% ▼ −1.22% −0.63% vs SPY
- Sep 29, 20266w ago 8-K Bullish 7/10 Entry $0.8501 to $0.8064 Now $0.5380 −36.71% ▼ −5.14% −7.09% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9640 to $0.8501 Now $0.5380 −44.19% ▼ −11.82% −10.63% vs SPY
- Sep 1, 202610w ago 8-K Neutral 6/10 Entry $0.8800 to $0.7973 Now $0.5380 −38.86% ▼ −9.40% −9.48% vs SPY
- Aug 17, 202613w ago 144 Neutral 2/10 Entry $0.8680 to $0.9387 Now $0.5380 −38.02% ▲ +8.15% +8.35% vs SPY
- Jul 6, 202619w ago 8-K Bearish 6/10 Entry $0.8340 to $0.7834 Now $0.5380 +35.49% ▲ +6.07% +6.56% vs SPY
- Jun 16, 202621w ago Press Release Neutral 5/10 Entry $0.8918 to $0.9346 Now $0.5380 −39.67% ▲ +4.80% +7.03% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $0.8125 to $0.9312 Now $0.5380 −33.78% ▲ +14.61% +14.18% vs SPY
- Jun 9, 202622w ago Press Release Neutral 4/10 Entry $0.9900 to $0.8686 Now $0.5380 −45.66% ▼ −12.26% −14.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers